ADC Therapeutics SA - ESG Rating & Company Profile powered by AI
If you work at ADC Therapeutics SA and you wish to licence your ESG aseessment, please get in touch. This analysis of ADC Therapeutics SA leverages data from across the web and also from public documents by ADC Therapeutics SA. The Disclosure rating includes seventeen UN SDGs including: 'Good Health & Wellbeing', 'Decent Work & Economic Growth' and 'Partnerships for the Goals'.
ADC Therapeutics SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.0; made up of an environmental score of 4.8, social score of 4.8 and governance score of 5.3.
5.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 999 | Xeris Pharmaceuticals Inc | 5.1 | High |
| 999 | Vascular Biogenics Ltd | 5.1 | High |
| 1047 | ADC Therapeutics SA | 5.0 | High |
| 1047 | Anixa Biosciences Inc | 5.0 | High |
| 1047 | Amarin Corporation PLC | 5.0 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does ADC Therapeutics SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes ADC Therapeutics SA disclose current and historical energy intensity?
Sign up for free to unlockDoes ADC Therapeutics SA report the average age of the workforce?
Sign up for free to unlockDoes ADC Therapeutics SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes ADC Therapeutics SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes ADC Therapeutics SA disclose cybersecurity risks?
Sign up for free to unlockDoes ADC Therapeutics SA offer flexible work?
Sign up for free to unlockDoes ADC Therapeutics SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes ADC Therapeutics SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes ADC Therapeutics SA conduct supply chain audits?
Sign up for free to unlockDoes ADC Therapeutics SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes ADC Therapeutics SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes ADC Therapeutics SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes ADC Therapeutics SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes ADC Therapeutics SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes ADC Therapeutics SA disclose water use targets?
Sign up for free to unlockDoes ADC Therapeutics SA have careers partnerships with academic institutions?
Sign up for free to unlockDid ADC Therapeutics SA have a product recall in the last two years?
Sign up for free to unlockDoes ADC Therapeutics SA disclose incidents of discrimination?
Sign up for free to unlockDoes ADC Therapeutics SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas ADC Therapeutics SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes ADC Therapeutics SA disclose parental leave metrics?
Sign up for free to unlockDoes ADC Therapeutics SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes ADC Therapeutics SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes ADC Therapeutics SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes ADC Therapeutics SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes ADC Therapeutics SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes ADC Therapeutics SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs ADC Therapeutics SA involved in embryonic stem cell research?
Sign up for free to unlockDoes ADC Therapeutics SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes ADC Therapeutics SA disclose its waste policy?
Sign up for free to unlockDoes ADC Therapeutics SA report according to TCFD requirements?
Sign up for free to unlockDoes ADC Therapeutics SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes ADC Therapeutics SA disclose energy use targets?
Sign up for free to unlockDoes ADC Therapeutics SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes ADC Therapeutics SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for ADC Therapeutics SA
These potential risks are based on the size, segment and geographies of the company.
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.